» Articles » PMID: 9921411

A Prophylactic and Therapeutic AIDS Vaccine Containing As a Component the Innocuous Tat Toxoid

Overview
Date 1999 Jan 28
PMID 9921411
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Extracellular Tat can act as a viral toxin on uninfected cells of different tissues, including the CNS and the immune system, thus in order to immunize humans against Tat we have prepared a biologically inactivated but immunogenic Tat (Tat Toxoid). Tat Toxoid is not toxic in mice even at high doses. It triggers high levels of specific Tat Abs in the mouse and rabbit. Furthermore, in humans Tat Toxoid immunization was safe and induced in seronegatives persistent high levels of Tat Abs and in immunodeficient patients a significant rise of these specific Abs. Facing acute HIV-1 infection, the presence of high level of circulating Tat Abs promoted by Tat Toxoid vaccine should prevent Tat-induced immunosuppression and allow anti-HIV-1 cellular response to develop. As a consequence, early release of beta-chemokines could enhance host resistance towards HIV-1, and, in infected people, inhibit viral replication and evolution towards AIDS.

Citing Articles

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Fouts T, Bagley K, Prado I, Bobb K, Schwartz J, Xu R Proc Natl Acad Sci U S A. 2015; 112(9):E992-9.

PMID: 25681373 PMC: 4352796. DOI: 10.1073/pnas.1423669112.


Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.

Pauza C, Trivedi P, Wallace M, Ruckwardt T, Le Buanec H, Lu W Proc Natl Acad Sci U S A. 2000; 97(7):3515-9.

PMID: 10725402 PMC: 16271. DOI: 10.1073/pnas.97.7.3515.